Targeting integrin pathways: mechanisms and advances in therapy

X Pang, X He, Z Qiu, H Zhang, R Xie, Z Liu… - … and Targeted Therapy, 2023 - nature.com
Integrins are considered the main cell-adhesion transmembrane receptors that play
multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in …

[PDF][PDF] Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis

J May, JA Mitchell, RG Jenkins - Journal of Clinical …, 2023 - Am Soc Clin Investig
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with poor
survival. The incidence and mortality of IPF are rising, but treatment remains limited …

Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities

S Li, C Sampson, C Liu, H Piao, HX Liu - Cell Communication and …, 2023 - Springer
Integrins are transmembrane receptors that possess distinct ligand-binding specificities in
the extracellular domain and signaling properties in the cytoplasmic domain. While most …

Reviewing the regulators of COL1A1

H Devos, J Zoidakis, MG Roubelakis… - International Journal of …, 2023 - mdpi.com
The collagen family contains 28 proteins, predominantly expressed in the extracellular
matrix (ECM) and characterized by a triple-helix structure. Collagens undergo several …

Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases

M Ezzo, B Hinz - Pharmacology & therapeutics, 2023 - Elsevier
The ability of cells to sense and respond to changes in mechanical environment is vital in
conditions of organ injury when the architecture of normal tissues is disturbed or lost. Among …

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

JW Jackson, FC Streich Jr, A Pal, G Coricor… - Science …, 2024 - science.org
Inhibitors of the transforming growth factor–β (TGF-β) pathway are potentially promising
antifibrotic therapies, but nonselective simultaneous inhibition of all three TGF-β homologs …

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

A Roy, L Shi, A Chang, X Dong, A Fernandez… - Nature …, 2023 - nature.com
Abstract The RGD (Arg-Gly-Asp)-binding integrins αvβ6 and αvβ8 are clinically validated
cancer and fibrosis targets of considerable therapeutic importance. Compounds that can …

Proteomic biomarkers of survival in idiopathic pulmonary fibrosis

JM Oldham, Y Huang, S Bose, SF Ma… - American Journal of …, 2024 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis (IPF) causes progressive lung scarring and high
mortality. Reliable and accurate prognostic biomarkers are urgently needed. Objectives: To …

Current and future treatment landscape for idiopathic pulmonary fibrosis

F Bonella, P Spagnolo, C Ryerson - Drugs, 2023 - Springer
Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

L Lancaster, V Cottin, M Ramaswamy… - American Journal of …, 2024 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes
progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives …